Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes

CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.PMID:36222710 | DOI:10.1158/1078-0432.CCR-22-1206

Source: Clinical Cancer Research - October 12, 2022 Category: Cancer & Oncology Authors: Nicola S Meagher Kylie L Gorringe Matthew J Wakefield Adelyn Bolithon Chi Nam Ignatius Pang Derek S Chiu Michael S Anglesio Kylie-Ann Mallitt Jennifer A Doherty Holly R Harris Joellen M Schildkraut Andrew Berchuck Kara L Cushing-Haugen Ksenia Chezar Angel Source Type: research